Prostate Cancer

The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet. Read More ›

IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy

The IsoPSA assay holds promise for improved diagnostic accuracy, said Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic, OH, at the 2016 American Urological Association annual meeting.

Read More ›

“A shorter, hypofractionated schedule of radiation is noninferior to conventional radiation for disease control in men with intermediate-risk prostate cancer at a median follow-up of 6 years,” said lead investigator Charles N. Catton, MD, FRCPC, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, who presented the study results.

Read More ›

“Redirecting radical prostatectomy patients to high-volume providers is associated with better medical and oncologic outcomes, shorter length of stay, and fewer complications. Referrals within 100 miles are not only feasible but could save significant societal costs,” said Sarmad Sadeghi, MD, PhD, of the USC Norris Comprehensive Cancer Center, Los Angeles, CA, who presented the study results.

Read More ›

Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study. Read More ›

Regular Aspirin Use Reduces the Risk for Death from Prostate Cancer
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer, according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium. Read More ›

A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer. Read More ›

Genomic Test Supports Treatment Decisions in Prostate Cancer
A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare. Read More ›

New Prostate Cancer Biomarkers Can Predict Aggressive Disease in African Americans
It is well-known that African-American men have a higher incidence of prostate cancer and a greater mortality rate than American men of other races and ethnicities. Read More ›

Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer—an aggressive and rapidly progressing type of prostate cancer that is increasingly being recognized in patients with advanced disease and signals poor overall survival. Read More ›

Page 3 of 5

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication